Patents Assigned to Pozen Inc.
-
Patent number: 9161920Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: GrantFiled: October 16, 2014Date of Patent: October 20, 2015Assignee: Pozen Inc.Inventor: John R. Plachetka
-
Publication number: 20150202193Abstract: The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer.Type: ApplicationFiled: January 9, 2015Publication date: July 23, 2015Applicants: POZEN INC., HORIZON PHARMA USA, INC.Inventors: Brian AULT, Clara HWANG, Everardus Orlemans, John R. PLACHETKA, Mark SOSTEK
-
Publication number: 20150125524Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: ApplicationFiled: October 16, 2014Publication date: May 7, 2015Applicant: Pozen Inc.Inventor: John R. PLACHETKA
-
Publication number: 20150079169Abstract: The present invention provides for novel formulations of clopidogrel in combination with proton pump inhibitors (PPI) and optionally with NSAIDs, for use as improved antiplatelet therapies in stroke and cardiovascular indications. The invention provides the delivery of clopidogrel in pulses or waves, such that the total dose is phased/spread out over time and, advantageously, combined with omeprazole in a way to minimize the conflicting actions these two drugs may have on each other. In addition, the invention also provides the delivery of clopidogrel and a PPI, and optionally aspirin, in a sequential (orderly) manner that would allow for the delivery and metabolism of clopidogrel first, followed by the PPI, and thereafter optionally aspirin. A particular mode of the invention involves the combination of clopidogrel with coformulated immediate release omeprazole+enteric coated aspirin.Type: ApplicationFiled: September 14, 2012Publication date: March 19, 2015Applicant: POZEN INC.Inventor: John R. Plachetka
-
Patent number: 8945621Abstract: The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer.Type: GrantFiled: June 24, 2010Date of Patent: February 3, 2015Assignees: Pozen Inc., Horizon Pharma USA, Inc.Inventors: Brian Ault, Clara Hwang, Everardus Orlemans, John R Plachetka, Mark Sostek
-
Publication number: 20150024042Abstract: The present invention provides for novel formulations of clopidogrel to provide for phased/spaced release for use as improved antiplatelet therapies in stroke and cardiovascular indications.Type: ApplicationFiled: September 14, 2012Publication date: January 22, 2015Applicant: POZEN INC.Inventor: John R. Plachetka
-
Publication number: 20140370088Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising acetylsalicylic acid, or pharmaceutically acceptable salt thereof, and omeprazole, or pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 27, 2012Publication date: December 18, 2014Applicant: POZEN INC.Inventor: John R. Plachetka
-
Patent number: 8865190Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: GrantFiled: April 1, 2014Date of Patent: October 21, 2014Assignee: Pozen Inc.Inventor: John R. Plachetka
-
Patent number: 8858996Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: GrantFiled: April 3, 2014Date of Patent: October 14, 2014Assignee: Pozen Inc.Inventor: John R. Plachetka
-
Patent number: 8852636Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: GrantFiled: October 3, 2013Date of Patent: October 7, 2014Assignee: Pozen Inc.Inventor: John R. Plachetka
-
Publication number: 20140212489Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: ApplicationFiled: April 3, 2014Publication date: July 31, 2014Applicant: Pozen Inc.Inventor: John R. PLACHETKA
-
Publication number: 20140212572Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: ApplicationFiled: April 1, 2014Publication date: July 31, 2014Applicant: Pozen Inc.Inventor: John R. PLACHETKA
-
Publication number: 20140141080Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: ApplicationFiled: October 3, 2013Publication date: May 22, 2014Applicant: Pozen Inc.Inventor: John R. PLACHETKA
-
Patent number: 8557285Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: GrantFiled: August 23, 2011Date of Patent: October 15, 2013Assignee: Pozen Inc.Inventor: John R. Plachetka
-
Publication number: 20130078305Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: ApplicationFiled: May 18, 2012Publication date: March 28, 2013Applicant: POZEN, INC.Inventor: John R. Plachetka
-
Publication number: 20120177736Abstract: The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising aspirin, or a pharmaceutically acceptable salt thereof, and an acid inhibitor to the at risk patient and thereby decreasing the patient's risk of developing an ulcer.Type: ApplicationFiled: January 6, 2012Publication date: July 12, 2012Applicant: POZEN INC.Inventor: JOHN R. PLACHETKA
-
Patent number: 8206741Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: GrantFiled: May 16, 2005Date of Patent: June 26, 2012Assignee: POZEN Inc.Inventor: John R. Plachetka
-
Publication number: 20110275691Abstract: The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT1B/1D agonist.Type: ApplicationFiled: July 15, 2011Publication date: November 10, 2011Applicant: POZEN, INC.Inventor: John R. Plachetka
-
Patent number: 8022095Abstract: The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT1B/1D agonist.Type: GrantFiled: April 16, 2003Date of Patent: September 20, 2011Assignee: Pozen, Inc.Inventor: John R. Plachetka
-
Publication number: 20110008432Abstract: The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising aspirin, or a pharmaceutically acceptable salt thereof, and an acid inhibitor to the at risk patient and thereby decreasing the patient's risk of developing an ulcer.Type: ApplicationFiled: June 24, 2010Publication date: January 13, 2011Applicant: POZEN INC.Inventor: John R. Plachetka